New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?

Puhr, Hannah Christina; Preusser, Matthias; Prager, Gerald W.

doi:10.3390/cancers12020301

Cited by 8 publications

(7 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, taking into account the differences in population and other influencing factors, I still believe that apatinib would benefit for gastric cancer patients. Furthermore, with the development of immune checkpoint inhibitor therapy, the combination of ICIs with chemotherapy and targeted therapy is promising (22).…”

Section: Discussionmentioning

confidence: 99%

Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study

Jing¹,

Bai²,

Zhang³

et al. 2021

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: The current management of advanced gastric or gastro-oesophageal junction adenocarcinoma remains unsatisfactory. We investigated the efficacy and safety of the combination therapy of apatinib and S-1, considering the potential advantage of home-based treatment without hospital admission, in patients with platinum-refractory gastric or gastro-oesophageal junction adenocarcinoma. Methods:In this open-label, single-arm, phase 2 trial, in each 21-day cycle, eligible patients received apatinib at an initial dose of 500 mg once daily continuously and S-1 at a dose of 40-60 mg twice daily on days 1-14 until the trail was discontinued disease progression, development of intolerable toxicity, or withdrawal of consent. The primary endpoints were progression-free survival. The secondary endpoints were objective response rates, disease control rates, and safety, and overall survival. This study was registered at ClinicalTrials.gov, NCT04338438.Results: Between April 2015 and May 2019, we included 37 patients with advanced gastric or gastrooesophageal junction adenocarcinoma refractory to first-line platinum-containing therapy. At the data cutoff, the 6-month progression-free survival was 31.5%, the median progression-free survival and overall survival were 4.2 months (95% CI: 3.50-4.90) and 8.2 months (95% CI: 4.69-11.71), respectively. Of 37 eligible patients, 8 (21.6%) patients reached objective responses, 31 (83.8%) patients reached disease control. Grade 3 or 4 adverse events occurred in 8 (21.6%) patients, including hand-foot syndrome, hypertension, and diarrhea, etc. Conclusions:The combination of Apatinib and S-1 showed promising efficacy and manageable toxicity as a home-based, second-line therapy in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma, especially for the elder patients with poor performance status.Trial Registration: NCT04338438.

show abstract

Section: Discussionmentioning

confidence: 99%

Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study

Jing¹,

Bai²,

Zhang³

et al. 2021

J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…To date, gastrectomy and chemotherapy are still the main therapeutic options for patients with GC ( 2 ). Many new agents, such as pembrolizumab, avelumab and rilitumumab, have been investigated in patients with GC but didn’t demonstrate efficacy ( 3 , 4 ). Due to its high prevalence, low survival, and limited treatment choices, GC remains an important clinical practice challenge.…”

Section: Introductionmentioning

confidence: 99%

Gastric cancer risk-scoring system based on analysis of a competing endogenous RNA network

Liu¹,

Li²,

Huang³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background Long noncoding RNAs (lncRNAs) can play vital roles in tumor initiation, progression, invasion, and metastasis. However, the functional role of the lncRNA-based competing endogenous RNA (ceRNA) networks in gastric cancer (GC) is still unclear. We aimed to identify novel lncRNAs and their association with GC prognosis. Methods The lncRNA, miRNA, and mRNA expression profiles of GC patients data were obtained from The Cancer Genome Atlas (TCGA) database. Differentially expressed genes (DEGs) were identified using the edge-R package. Then, the relationship among lncRNAs-miRNAs-mRNAs was integrated into a constructed ceRNA network with Cytoscape software. Using Cox regression analysis, a risk score system based on DEGs associated with patient prognosis in GC was established. Finally, a nomogram was founded to predict the prognosis of GC patients. Results A total of 971 differentially expressed lncRNAs (DElncRNAs), 144 differentially expressed miRNAs (DEmiRNAs) and 2,789 differentially expressed mRNAs (DEmRNAs) were identified and found to be associated with GC risk. Using the bioinformatics method, a ceRNA network involving 62 DElncRNAs, 21 DEmiRNAs and 59 DEmRNAs was constructed. Based on the results of the Cox regression analysis, a risk-scoring system involving 3 lncRNAs (i.e., ADAMTS9-AS1, C15orf54, and AL391152.1) was set up for the survival analysis of GC patients. The area under the receiver operating characteristic (ROC) curve for the risk-scoring system was 0.674, with a C-index of 0.64 [95% confidence interval (CI): 0.59–0.69, P=2.806485e−08]. Univariate and multivariate Cox regression analyses demonstrated that the risk-scoring system was an independent prognostic factor for GC. The risk-scoring system is positively associated with advanced tumor grade. The expression of these 3 lncRNAs were validated in GEPIA database. A nomogram based on these 3 lncRNAs was created to predict the prognosis of GC patients. Conclusions Our study established a novel lncRNA-expression-based ceRNA network and an ADAMTS9-AS1-C15orf54-AL391152.1-based risk-scoring system, which can be used to predict the prognosis of GC patients.

show abstract

“…No change of survival outcome in patients with gastroesophageal tumors had been observed for decades. This trend now seems to have changed, since various immunotherapy compounds have been shown to be beneficial in patients with gastroesophageal tumors, both in advanced and metastatic setting [11]. However, novel data raised many critical questions: Which biomarker is appropriate for daily clinical use: PD-L1 TPS or CPS?…”

Section: Discussionmentioning

confidence: 99%

ASCO 2021–Gastroesophageal tumor highlights

Ilhan-Mutlu

2021

memo

Self Cite

View full text Add to dashboard Cite

SummaryThe oncological community witnessed several practice-changing clinical reports in this years’ annual congress of the American Society of Clinical Oncology (ASCO). Many immunotherapeutic agents were shown to be beneficial for upper gastrointestinal tumors. For advanced squamous cell carcinoma, immunotherapy and chemotherapy combinations revealed by the CheckMate 648 and ESCORT-1st trials have been implemented into the clinical practice. The updates on the CheckMate 649 and CheckMate 577 trials again underlined the significant clinical contribution of nivolumab in advanced and localized gastroesophageal cancer, respectively. However, this effect seems to be dependent to PD-L1 expression. Not only immunotherapy trials, but also targeted therapy studies such as the FIGHT trial investigating the anti-FGFR2b monoclonal antibody bemarituzumab attracted huge interest, not only due to extension of survival in experimental group, but also due to the innovative design of this trial. This review summarizes the highlights regarding gastroesophageal tumors at the ASCO 2021 congress.

show abstract

New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?

Cited by 8 publications

References 84 publications

Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study

Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study

Gastric cancer risk-scoring system based on analysis of a competing endogenous RNA network

ASCO 2021–Gastroesophageal tumor highlights

Contact Info

Product

Resources

About